Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes
- 20 January 2006
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 189 (1), 236-240
- https://doi.org/10.1016/j.atherosclerosis.2005.12.007
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery DiseaseCirculation Research, 2005
- Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine DimethylaminohydrolaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Atherosklerose und Urämie: Die Bedeutung nicht-traditioneller RisikofaktorenWiener klinische Wochenschrift, 2003
- Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective studyThe Lancet, 2001
- Reduced Urinary Excretion of Nitric Oxide Metabolites and Increased Plasma Levels of Asymmetric Dimethylarginine in Men with Essential HypertensionJournal of Cardiovascular Pharmacology, 1999
- Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial DysfunctionCirculation, 1998
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureThe Lancet, 1992
- Hyperhomocysteinemia: An Independent Risk Factor for Vascular DiseaseNew England Journal of Medicine, 1991
- Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke.Stroke, 1990
- Diabetes and cardiovascular disease. The Framingham studyJAMA, 1979